Vaxcyte, Inc. filings document a clinical-stage vaccine company developing bacterial-disease vaccine candidates and raising capital through registered common stock transactions. Recent Form 8-K reports cover financial results, business updates tied to VAX-31 and other pipeline programs, an underwritten common stock offering, an at-the-market sales agreement under an effective Form S-3 shelf registration, and a manufacturing services agreement for drug product supply.
Proxy materials disclose shareholder voting matters, board and governance information, executive compensation, and equity-plan matters. The filing record also identifies Vaxcyte’s Nasdaq-listed common stock under PCVX and formalizes material agreements, financing arrangements, and corporate disclosures related to its vaccine development and manufacturing strategy.
Vaxcyte, Inc. EVP, Chief Scientific Officer and COO Jim Wassil exercised options to acquire 2,250 common shares at $5.35 per share on October 1, 2026. He also sold 2,155 shares at a weighted-average $56.654 and 95 shares at a weighted-average $57.094. The sales were made under a Rule 10b5-1 trading plan adopted December 9, 2025. The derivative-security row reports 64,398 stock options following the transaction.
Vaxcyte, Inc. officer James Wassil reported a proposed sale of 2,250 common shares, with an approximate sale date of October 1, 2026. The notice lists an aggregate market value of $127,642.50 and says the shares were acquired from the issuer through exercise of a stock option, with cash payment. It also lists earlier sales dated July 1, August 3, September 1, September 4 and September 9, 2026.
Vaxcyte, Inc. (PCVX) reports that Chief Executive Officer and director Grant Pickering surrendered 17,056 shares of Common Stock on September 8, 2026 to cover applicable tax withholding obligations arising from the vesting of restricted stock units, at a reference price of $60.36 per share. After this tax-withholding disposition, he directly holds 429,902 shares of Vaxcyte common stock and also has indirect holdings through trusts established for his son and daughter.
Vaxcyte, Inc. (PCVX) reported that President and CFO Andrew Guggenhime had 7,155 shares of common stock withheld on September 8, 2026 to cover tax liabilities arising from the vesting of restricted stock units, at a reference price of $60.36 per share. After this tax-withholding disposition, he holds 95,316 shares directly, plus 61,850 shares held indirectly through ALG 2025 GRAT Holdings LLC, a grantor retained annuity trust for which he is annuitant and trustee.
Vaxcyte, Inc. (PCVX) reported that Chief Technical Ops Officer Harpreet S. Dhaliwal had 7,651 shares of common stock surrendered on September 8, 2026 to cover tax withholding obligations arising from vesting RSUs. The transaction was a share disposition for tax purposes, leaving 68,085 shares held directly after the event. No Rule 10b5-1 trading plan is reported for this transaction.
Vaxcyte, Inc. (PCVX) reported that Elvia Cowan, its Senior Vice President, Finance and Chief Accounting Officer, surrendered 1,327 shares of common stock on September 8, 2026 to cover tax withholding obligations arising from the vesting of restricted stock units. The shares were valued at $60.36 per share for this purpose, and Cowan now holds 27,860 shares of Vaxcyte common stock directly. This was a tax-withholding share disposition, not an open-market sale, and no Rule 10b5-1 trading plan is reported.
Vaxcyte, Inc. (PCVX) executive Jim Wassil, EVP, Chief Scientific Officer and COO, reported selling a total of 2,715 shares of common stock in open-market transactions on September 4 and 9, 2026, at weighted-average prices around $61.16 and $59.52, respectively, under a Rule 10b5-1 trading plan adopted on December 9, 2025. On September 8, 2026, 5,459 shares were surrendered to the issuer to cover tax withholding obligations upon RSU vesting.
Vaxcyte, Inc. (PCVX) reported that Chief Medical Officer Luis Jodar received new equity awards on September 4, 2026. He was granted 52,632 restricted stock units, each representing one share of common stock, and a stock option for 88,254 shares at an exercise price of $61.16 per share, expiring September 4, 2036. The RSUs vest 25% on September 7, 2027 and 12.5% every six months thereafter, and the option vests 25% on August 31, 2027 and monthly thereafter, in each case subject to his continued service. No Rule 10b5-1 trading plan is reported.
Vaxcyte, Inc. (PCVX) reported the initial equity holdings of Chief Medical Officer Luis Jodar on a Form 3. The filing shows a stock option to purchase 23,941 shares of common stock at an exercise price of $47.30 per share, expiring on May 22, 2036.
According to the disclosure, these options vest monthly over 36 months starting from May 22, 2026, contingent on Dr. Jodar’s continuous service with the company through each vesting date.
Vaxcyte, Inc. (PCVX) is the issuer for which officer James Wassil has filed a notice under Rule 144 to sell common stock. The notice covers a proposed sale of 1,334 shares of common stock, with an indicated aggregate value of $80,026.66, following an RSU vest on September 7, 2026.
The filing also lists recent sales of Vaxcyte common stock for Wassil during the prior three months, including separate transactions of 2,250 shares on July 1, 2026, 2,250 shares on August 3, 2026, 3,477 shares on September 1, 2026, and 1,381 shares on September 4, 2026, all executed through a broker.